What is EVELO BIOSCIENCES INC's earnings per share (EPS)?

EVELO BIOSCIENCES INC (EVLO) reported diluted earnings per share of -$1.31 for fiscal year 2022. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

EVELO BIOSCIENCES INC (EVLO) Financials

EVLO

FY2022 annual

Net Income -$114.5M +6.3% YoY

EPS (Diluted) -$1.31 YoY not available

Free Cash Flow -$101.9M -3.7% YoY

Operating Cash Flow -$101.2M -4.7% YoY

Market Cap $9K as of Sep 2, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2022

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2023

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2023, ended Sep 30, 2023 Reported Nov 9, 2023 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2023, filed Nov 9, 2023. Each column of the statement tables below links to the filing it was taken from.

This page shows EVELO BIOSCIENCES INC (EVLO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

EVELO BIOSCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

EVELO BIOSCIENCES INC passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

EVELO BIOSCIENCES INC reported a net loss of $114.5M while operations used $101.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$11.0M

YoY+61.5%

QoQ+42.7%

EVELO BIOSCIENCES INC's EBITDA was -$11.0M in Q3 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.5% from the same quarter a year earlier. Against the prior quarter it is up 42.7%.

Net Income

-$12.4M

YoY+59.5%

QoQ+41.4%

EVELO BIOSCIENCES INC reported -$12.4M in net income in Q3 2023. This represents an increase of 59.5% from the same quarter a year earlier. Against the prior quarter it is up 41.4%.

EPS (Diluted)

-$0.71

EVELO BIOSCIENCES INC earned -$0.71 per diluted share (EPS) in Q3 2023.

Revenue

Not reported for Q3 2023.

Cash & Balance Sheet

Free Cash Flow

-$10.5M

YoY+53.7%

QoQ+47.3%

EVELO BIOSCIENCES INC recorded an outflow of $10.5M in free cash flow in Q3 2023, representing a cash shortfall after capex. This represents an increase of 53.7% from the same quarter a year earlier. Against the prior quarter it is up 47.3%.

Cash & Debt

$17.3M

YoY-75.0%

QoQ+126.5%

5Y CAGR-26.4%

EVELO BIOSCIENCES INC held $17.3M in cash against $0 in long-term debt as of Q3 2023, with $39.8M of liabilities due within a year.

Shares Outstanding

19M

5Y CAGR-9.8%

EVELO BIOSCIENCES INC had 19M shares outstanding in Q3 2023.

Dividends Per Share

Not reported for Q3 2023.

Margins & Returns

None of these metrics is reported for Q3 2023.

Capital Allocation

R&D Spending

$6.5M

YoY-70.4%

QoQ-50.2%

EVELO BIOSCIENCES INC invested $6.5M in research and development in Q3 2023. This represents a decrease of 70.4% from the same quarter a year earlier. Against the prior quarter it is down 50.2%.

Capital Expenditures

$47K

YoY+422.2%

5Y CAGR-50.4%

EVELO BIOSCIENCES INC invested $47K in capex in Q3 2023, funding long-term assets and infrastructure. This represents an increase of 422.2% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2023.

EVLO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVLO quarterly income statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
R&D Expenses	N/A	$78.6M-6.1%	$83.6M+20.1%	$69.6M+10.3%	$63.1M+58.3%	$39.9M+99.9%	$20.0M+118.5%	$9.1M
SG&A Expenses	N/A	$29.9M-5.8%	$31.8M+42.6%	$22.3M-4.1%	$23.2M+27.5%	$18.2M+140.5%	$7.6M+94.7%	$3.9M
Operating Income	N/A	-$108.5M+6.0%	-$115.4M-25.6%	-$91.9M-6.4%	-$86.4M-48.6%	-$58.1M-111.0%	-$27.5M-111.4%	-$13.0M
EBITDA	N/A	-$106.4M+6.0%	-$113.2M-26.0%	-$89.9M-6.2%	-$84.6M-50.6%	-$56.2M-110.4%	-$26.7M-113.1%	-$12.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$900K+80.0%	$500K+66.7%	$300K
Income Tax	N/A	$930K+117.3%	$428K+4.6%	$409K+115.3%	$190K	$0	$0	N/A
Net Income	N/A	-$114.5M+6.3%	-$122.2M-30.4%	-$93.7M-9.6%	-$85.5M-50.1%	-$56.9M-103.0%	-$28.0M-110.4%	-$13.3M
EPS (Basic)	N/A	-$1.31+43.3%	-$2.31+2.5%	-$2.37	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$1.31	-$2.31+2.5%	-$2.37	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	87M	53M+34.0%	39M	N/A	N/A	N/A	N/A

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
R&D Expenses	$6.5M-70.4%	$13.0M-38.5%	$17.9M-7.6%	N/A	$21.9M-3.0%	$21.2M+2.7%	$19.3M-10.2%	N/A
SG&A Expenses	$3.9M-45.4%	$4.9M-41.3%	$7.0M-25.2%	N/A	$7.1M-29.5%	$8.4M+19.5%	$9.4M+57.9%	N/A
Operating Income	-$11.2M+61.5%	-$19.6M+33.8%	-$24.9M+13.4%	N/A	-$29.1M+11.2%	-$29.6M-7.0%	-$28.7M-4.6%	N/A
EBITDA	-$11.0M+61.5%	-$19.2M+34.1%	-$24.5M+13.3%	N/A	-$28.6M+11.1%	-$29.1M-7.1%	-$28.2M-4.8%	N/A
Interest Expense	$1.3M+18.2%	N/A	N/A	N/A	$1.1M	N/A	N/A	N/A
Income Tax	-$17K-115.9%	$233K+42.9%	$145K+25.0%	N/A	$107K-31.4%	$163K+207.5%	$116K-4.9%	N/A
Net Income	-$12.4M+59.5%	-$21.1M+30.9%	-$25.3M+15.1%	N/A	-$30.6M+9.4%	-$30.6M+3.3%	-$29.9M-5.9%	N/A
EPS (Basic)	-$0.71+87.5%	-$3.78+53.2%	-$0.23+58.9%	-$0.17+68.5%	-$5.66-798.4%	-$8.07-1267.8%	-$0.56-1.8%	-$0.54+14.3%
EPS (Diluted)	-$0.71	-$3.78	-$0.23	-$0.17	-$5.66	-$8.07	-$0.56-1.8%	-$0.54+14.3%
Diluted Shares (Avg)	17M	6M	111M	N/A	5M	4M	54M+4.4%	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

EVLO Balance Sheet

EVLO quarterly balance sheet

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$64.4M-26.7%	$87.9M-3.1%	$90.6M-0.3%	$90.9M-43.1%	$159.9M+265.1%	$43.8M	N/A
Current Assets	$51.6M-27.4%	$71.0M+0.1%	$71.0M-12.4%	$81.0M-46.6%	$151.6M+291.0%	$38.8M	N/A
Cash & Equivalents	$47.9M-30.0%	$68.4M-0.6%	$68.9M-11.5%	$77.8M-16.4%	$93.1M+143.4%	$38.2M+142.3%	$15.8M
Short-Term Investments	$0	$0	$0	$0-100.0%	$54.8M	$0	$0
Accounts Receivable	N/A	N/A	$0	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$69.4M-12.3%	$79.2M+31.7%	$60.2M+95.8%	$30.7M+34.1%	$22.9M-76.7%	$98.5M	N/A
Current Liabilities	$12.4M-28.6%	$17.4M-12.5%	$19.8M+103.6%	$9.7M+5.5%	$9.2M+140.6%	$3.8M	N/A
Non-Current Liabilities	$57.0M-7.8%	$61.8M+53.4%	$40.3M+92.2%	$21.0M+53.3%	$13.7M-85.5%	$94.7M	N/A
Long-Term Debt	$43.6M-6.3%	$46.6M+54.9%	$30.0M+53.0%	$19.6M+59.6%	$12.3M+23.5%	$10.0M	N/A
Total Equity	-$5.0M-157.6%	$8.7M-71.6%	$30.5M-49.4%	$60.2M-56.0%	$136.9M+350.3%	-$54.7M-93.1%	-$28.3M
Retained Earnings	-$529.2M-27.6%	-$414.7M-41.8%	-$292.5M-47.1%	-$198.9M-75.4%	-$113.4M-101.0%	-$56.4M	N/A

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Total Assets	$20.6M-76.1%	$20.8M-81.4%	$42.0M-28.7%	$64.4M-26.7%	$86.3M-25.9%	$111.9M-22.9%	$58.8M-61.6%	$87.9M-3.1%
Current Assets	$18.9M-73.8%	$11.3M-88.4%	$30.1M-30.2%	$51.6M-27.4%	$72.3M-26.1%	$97.0M-23.2%	$43.1M-67.9%	$71.0M+0.1%
Cash & Equivalents	$17.3M-75.0%	$7.6M-91.7%	$27.5M-30.7%	$47.9M-30.0%	$69.1M-28.0%	$92.0M-25.4%	$39.6M-68.2%	$68.4M-0.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$47.3M-38.5%	$66.9M-12.2%	$69.4M-8.3%	$69.4M-12.3%	$77.0M-7.7%	$76.3M-8.1%	$75.6M+16.0%	$79.2M+31.7%
Current Liabilities	$39.8M+47.7%	$55.5M+159.0%	$57.2M+254.0%	$12.4M-28.6%	$26.9M+29.9%	$21.4M+8.3%	$16.2M-13.6%	$17.4M-12.5%
Non-Current Liabilities	$7.6M-84.9%	$11.4M-79.2%	$12.1M-79.6%	$57.0M-7.8%	$50.1M-20.1%	$54.8M-13.2%	$59.5M+27.9%	$61.8M+53.4%
Long-Term Debt	$0-100.0%	$0-100.0%	$0-100.0%	$43.6M-6.3%	$36.6M-21.2%	$40.7M-12.3%	$44.8M+53.0%	$46.6M+54.9%
Total Equity	-$26.7M-386.1%	-$46.1M-229.4%	-$27.4M-63.0%	-$5.0M-157.6%	$9.3M-71.8%	$35.6M-42.6%	-$16.8M-119.1%	$8.7M-71.6%
Retained Earnings	-$588.0M-16.3%	-$575.7M-21.2%	-$554.6M-24.7%	-$529.2M-27.6%	-$505.7M-31.0%	-$475.1M-34.9%	-$444.6M-38.6%	-$414.7M-41.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

EVLO Cash Flow Statement

EVLO quarterly cash flow statement

Metric	TTM	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$73.7M	-$101.2M-4.7%	-$96.7M-32.4%	-$73.1M-1.5%	-$72.0M-52.2%	-$47.3M-103.2%	-$23.3M-88.9%	-$12.3M
Depreciation & Amortization	N/A	$2.1M-7.0%	$2.2M+9.4%	$2.0M+14.9%	$1.8M-8.8%	$1.9M+132.0%	$834K+68.5%	$495K
Stock-Based Compensation	N/A	$15.2M-4.3%	$15.8M+87.1%	$8.5M+3.7%	$8.2M+34.8%	$6.1M+292.9%	$1.5M+268.0%	$419K
Capital Expenditures	$287K	$622K-59.1%	$1.5M+15.0%	$1.3M-56.4%	$3.0M-44.5%	$5.5M+213.5%	$1.7M+39.4%	$1.3M
Free Cash Flow	-$74.0M	-$101.9M-3.7%	-$98.2M-32.1%	-$74.4M+0.8%	-$75.0M-42.2%	-$52.7M-110.9%	-$25.0M-84.4%	-$13.6M
Investing Cash Flow	$273K	-$622K+58.0%	-$1.5M-12.6%	-$1.3M-102.5%	$52.0M+186.4%	-$60.1M-3351.7%	-$1.7M-118.8%	$9.3M
Financing Cash Flow	$20.8M	$81.7M-16.3%	$97.5M+49.0%	$65.5M+1211.4%	$5.0M-96.9%	$162.0M+230.9%	$49.0M+211.1%	$15.7M

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Operating Cash Flow	-$10.4M+53.9%	-$19.8M+25.3%	-$20.3M+29.9%	-$23.2M+16.7%	-$22.6M+16.9%	-$26.5M-71.9%	-$28.9M-10.1%	-$27.8M-46.9%
Depreciation & Amortization	$200K-60.0%	$400K-20.0%	$445K-13.9%	$523K-2.8%	$500K-16.7%	$500K0.0%	$517K-3.5%	$538K+0.9%
Stock-Based Compensation	$2.5M-28.5%	$2.4M-40.9%	$2.9M-32.0%	N/A	$3.5M-22.0%	$4.0M+6.0%	$4.3M+31.0%	N/A
Capital Expenditures	$47K+422.2%	$0-100.0%	$12K-92.2%	$228K-48.5%	$9K-98.9%	$232K-72.3%	$153K-51.3%	-$443K+8.3%
Free Cash Flow	-$10.5M+53.7%	-$19.8M+25.9%	-$20.3M+30.2%	-$23.4M+17.2%	-$22.6M+19.2%	-$26.8M-64.5%	-$29.1M-9.4%	-$28.3M-46.1%
Investing Cash Flow	$513K+5800.0%	$0+100.0%	-$12K+92.2%	-$228K-148.0%	-$9K+98.9%	-$232K+72.1%	-$153K+51.3%	$475K+216.1%
Financing Cash Flow	$19.2M+2790.2%	$0-100.0%	-$199K-270.1%	$1.7M+1480.2%	$665K+100.9%	$79.1M+427.3%	$117K-99.9%	-$126K-101.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

EVLO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVLO quarterly financial ratios

Metric	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Return on Equity	N/A	-1409.7%-1102.4pp	-307.3%-165.3pp	-142.0%-100.4pp	-41.6%	N/A	N/A
Return on Assets	-177.7%-38.7pp	-139.0%-35.7pp	-103.3%-9.3pp	-94.0%-58.4pp	-35.6%+28.4pp	-64.0%	N/A
Current Ratio	4.16+0.1x	4.09+0.5x	3.58-4.7x	8.31-8.1x	16.42+6.3x	10.10	N/A
Debt-to-Equity	N/A	5.37+4.4x	0.99+0.7x	0.33+0.2x	0.09	N/A	N/A

Metric	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-Q	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-K
Return on Equity	N/A	N/A	N/A	N/A	-327.5%-225.5pp	-85.7%-34.8pp	N/A	N/A
Return on Assets	-59.9%-24.5pp	-101.4%-74.1pp	-60.4%-9.6pp	N/A	-35.4%-6.4pp	-27.3%-5.5pp	-50.8%-32.3pp	N/A
Current Ratio	0.48-2.2x	0.20-4.3x	0.53-2.1x	4.16+0.1x	2.69-2.0x	4.52-1.9x	2.67-4.5x	4.09+0.5x
Debt-to-Equity	N/A	N/A	N/A	N/A	3.93+2.5x	1.14+0.4x	N/A	5.37+4.4x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$5.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
EVELO BIOSCIENCES INC EVLO	FY2022	N/A	-$114.5M	N/A	$9K	—
SCOPUS BIOPHARMA INC SCPS	FY2022	$0	N/A	N/A	$13K	—
RENOVACARE INC RCAR	FY2021	N/A	-$4.5M	N/A	$9K	—
VIRPAX PHARMS INC VRPX	FY2024	N/A	N/A	N/A	$5.7M	—
Q BIOMED INC. QBIO	FY2022	$284K	-$2.1M	N/A	$15K	—

Where EVELO BIOSCIENCES INC Ranks

Frequently Asked Questions

Is EVELO BIOSCIENCES INC profitable?

No, EVELO BIOSCIENCES INC (EVLO) reported a net income of -$114.5M in fiscal year 2022.

What is EVELO BIOSCIENCES INC's EBITDA?

EVELO BIOSCIENCES INC (EVLO) had EBITDA of -$106.4M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does EVELO BIOSCIENCES INC have?

As of fiscal year 2022, EVELO BIOSCIENCES INC (EVLO) had $47.9M in cash and equivalents against $43.6M in long-term debt.

What is EVELO BIOSCIENCES INC's free cash flow?

EVELO BIOSCIENCES INC (EVLO) recorded an outflow of $101.9M in free cash flow during fiscal year 2022. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is EVELO BIOSCIENCES INC's operating cash flow?

EVELO BIOSCIENCES INC (EVLO) recorded an outflow of $101.2M in operating cash flow during fiscal year 2022, representing cash used by core business activities.

What are EVELO BIOSCIENCES INC's total assets?

EVELO BIOSCIENCES INC (EVLO) had $64.4M in total assets as of fiscal year 2022, including both current and long-term assets.

What are EVELO BIOSCIENCES INC's capital expenditures?

EVELO BIOSCIENCES INC (EVLO) invested $622K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does EVELO BIOSCIENCES INC spend on research and development?

EVELO BIOSCIENCES INC (EVLO) invested $78.6M in research and development during fiscal year 2022.

How many shares does EVELO BIOSCIENCES INC have outstanding?

EVELO BIOSCIENCES INC (EVLO) had 111M shares outstanding as of fiscal year 2022.

What is EVELO BIOSCIENCES INC's current ratio?

EVELO BIOSCIENCES INC (EVLO) had a current ratio of 4.16 as of fiscal year 2022, which is generally considered healthy.

What is EVELO BIOSCIENCES INC's return on assets (ROA)?

EVELO BIOSCIENCES INC (EVLO) had a return on assets of -177.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is EVELO BIOSCIENCES INC's P/E ratio?

EVELO BIOSCIENCES INC (EVLO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2022). The market capitalization is $9K as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is EVELO BIOSCIENCES INC's price-to-sales ratio?

EVELO BIOSCIENCES INC (EVLO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $9K as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does EVELO BIOSCIENCES INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2022, EVELO BIOSCIENCES INC (EVLO) held $47.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $101.2M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is EVELO BIOSCIENCES INC's debt-to-equity ratio negative or not reported?

EVELO BIOSCIENCES INC (EVLO) has negative shareholder equity of -$5.0M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is EVELO BIOSCIENCES INC's Piotroski F-Score?

EVELO BIOSCIENCES INC (EVLO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are EVELO BIOSCIENCES INC's earnings high quality?

EVELO BIOSCIENCES INC (EVLO) reported a net loss of $114.5M while operations used $101.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.